Ornibel (Ethinylestradiol, Etonogestrel)

Ornibel is a combined hormonal contraceptive that acts on the reproductive endocrine pathway to prevent pregnancy.

• Contraception: Provides reliable prevention of ovulation and pregnancy when taken as prescribed.
• Menstrual cycle regulation: Helps to establish a more predictable menstrual bleeding pattern.
• Acne management: Reduces androgen‑driven skin lesions in women who require contraception.
• Endometriosis symptom relief: Alleviates pain associated with endometrial tissue outside the uterus.

• Ornibel combines ethinylestradiol, a synthetic estrogen, with etonogestrel, a progestin. The estrogen component suppresses hepatic production of follicle‑stimulating hormone, while the progestin blocks luteinizing hormone surge and induces cervical mucus changes, together inhibiting ovulation and creating an environment hostile to fertilisation.

Ornibel may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild stomach upset that often improves with continued use.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: temporary swelling or discomfort.
• Spotting between periods: light vaginal bleeding.
• Weight fluctuation: minor changes in body weight.
• Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in deep veins.
• Pulmonary embolism: clot migration to lung vessels.
• Stroke: cerebrovascular accident due to clot or hemorrhage.
• Myocardial infarction: heart attack risk, especially in smokers.
• Severe allergic reaction: rash, itching, swelling, or breathing difficulty.
• Liver dysfunction: jaundice or abnormal liver enzyme levels.

Before prescribing Ornibel, clinicians should evaluate individual risk factors and counsel patients on safe use.

• Smoking status: avoid in women over 35 who smoke due to increased thrombotic risk.
• Cardiovascular history: assess for hypertension, stroke, or clotting disorders.
• Liver disease: contraindicated in active liver disease.
• Migraine with aura: use with caution due to stroke risk.
• Breast cancer history: avoid in current or past estrogen‑sensitive malignancies.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ornibel can interact with several medicines that alter hormone metabolism or increase clot risk.

Major Interactions (Avoid)

• Antifungal azoles (ketoconazole, itraconazole): increase estrogen levels, raising thrombosis risk.
• Antiretroviral protease inhibitors (ritonavir): elevate plasma concentrations of both hormones.
• St. John’s wort: reduces contraceptive effectiveness by inducing hepatic enzymes.

Moderate Interactions (Monitor Closely)

• Anticonvulsants (carbamazepine, phenytoin): may lower hormone levels, decreasing efficacy.
• Antibiotics (rifampicin): can diminish contraceptive effect through enzyme induction.
• Diuretics (spironolactone): may increase potassium loss when combined with estrogen.